Stifel starts Rapport at buy, cites lead drug candidate RAP-219

duoogle Stifel has initiated coverage of Rapport Therapeutics ( NASDAQ: RAPP ) with a buy rating, citing the prospects of its lead drug candidate RAP-219 in the treatment of epilepsy. The investment firm said RAP-219 “offers a more selective way to inhibit AMPA signaling, rendering it an ideal mechanism for epilepsy.” It added that it was optimistic ahead of an expected readout from a proof-of-concept study in mid-2025.

Stifel set a price target of $35 for the stock. More on Rapport Therapeutics, Inc. No Holiday Break For Tesla, Constellation Brands, Comcast, And Trump Media Rapport Therapeutics Seeks IPO For CNS Treatment Programs J&J-backed Rapport Therapeutics prices IPO at $17 per share J&J-backed Rapport Therapeutics sets terms for $136M IPO Financial information for Rapport Therapeutics, Inc.

.